Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

While many people take supplements for brain health, the research supporting supplemental nutrients' effects on brain health ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

If you or a loved one is showing potential signs of age-related cognitive decline or dementia, you may want to seek help but not know the right type of health care provider to choose. That' ...

We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...

An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to ...

With announcements on new Alzheimer's drugs, the launch of essential care research partnerships, and funding more pioneering ways to transform the dementia landscape, 2024 has been the biggest year ...

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...